Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 2 to 6

Dexmedetomidine–midazolam versus ketamine–midazolam for emergence delirium in children

Official title: Prophylactic Effect of Dexmedetomidine-midazolam Versus Ketamine-midazolam on Emergence Delirium After Sevoflurane Anesthesia in Pediatric Cardiac Catheterization: A Randomized Controlled Study.

Run by Kasr El Aini Hospital · NCT07427446 · Data updated 2026-11-12

This test compares dexmedetomidine plus midazolam against ketamine plus midazolam to see which better prevents emergence delirium in children having heart catheterization under general anesthesia.

More Emergence Delirium trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages2 Years to 6 Years
SexAll
Enrollment50 (estimated)
SponsorKasr El Aini Hospital
Academic / other
Locations1 site (Cairo)
StatusRecruiting
StartedFebruary 1, 2026
Main results expectedDecember 2026
Study endsMarch 2027
Registry record updatedFebruary 27, 2026
Trial IDNCT07427446 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Children scheduled for elective cardiac catheterization under general anesthesia who do not have neurological or psychiatric disorders, are not on psychoactive medications, and have no significant systemic comorbidities are ideal candidates.

Probably not a fit

Children with neurological or psychiatric disorders, current psychoactive medication use, allergies to the study drugs, or significant systemic comorbidities would likely be excluded and may not benefit from the study interventions.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Fifty children scheduled for elective cardiac catheterization without local skin anesthesia are randomly assigned to one of two IV sedation regimens. The dexmedetomidine–midazolam group receives dexmedetomidine 1 µg/kg over 10 minutes and midazolam 0.1 mg/kg at induction, followed by dexmedetomidine 0.5 µg/kg/h and midazolam 0.1 mg/kg/h infusions for maintenance. The ketamine–midazolam group receives ketamine 1 mg/kg and midazolam 0.1 mg/kg at induction, followed by ketamine 1 mg/kg/h and midazolam 0.1 mg/kg/h infusions. Emergence delirium and recovery characteristics are compared between groups at a single center (Kasralainy Hospital, Cairo) in this Phase 4 interventional trial.

Why it matters

Potential benefit: If successful, the preferred regimen could reduce how often and how severely children experience emergence delirium after cardiac catheterization, improving recovery comfort and safety.

How similar studies have gone: Previous studies have shown dexmedetomidine can reduce emergence delirium in pediatric anesthesia while ketamine results are mixed, so this head-to-head comparison builds on some supporting evidence but direct comparisons are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Scheduled for elective cardiac catheterization under general anesthesia.

Exclusion Criteria:

* neurological disorder, psychiatric disease, or current psychoactive medication.
* allergy.
* significant systemic comorbidities.

Where it's running

  • Kasralainy Hospital
    Cairo, Egypt
    Recruiting

Study contacts

  • Principal investigator: Ahmed Elhaddad, Ass.prof. — Faculty of medicins,Cairo university
  • Study coordinator: Ahmed Elhaddad, Ass.prof.
  • Email: drblacksmith@gmail.com
  • Phone: 01224042847

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.